Moderna, Inc.

NasdaqGS:MRNA Stock Report

Market Cap: US$12.2b

Moderna Management

Management criteria checks 2/4

Moderna's CEO is Stéphane Bancel, appointed in Oct 2011, has a tenure of 14.17 years. total yearly compensation is $19.88M, comprised of 8.2% salary and 91.8% bonuses, including company stock and options. directly owns 5.62% of the company’s shares, worth $685.08M. The average tenure of the management team and the board of directors is 5.6 years and 11.6 years respectively.

Key information

Stéphane Bancel

Chief executive officer

US$19.9m

Total compensation

CEO salary percentage8.18%
CEO tenure14.2yrs
CEO ownership5.6%
Management average tenure5.6yrs
Board average tenure11.6yrs

Recent management updates

Recent updates

Moderna: Why I Am Selling The 'Relief Rally'

Dec 23

There's No Escaping Moderna, Inc.'s (NASDAQ:MRNA) Muted Revenues Despite A 28% Share Price Rise

Dec 19
There's No Escaping Moderna, Inc.'s (NASDAQ:MRNA) Muted Revenues Despite A 28% Share Price Rise

Moderna, Inc.'s (NASDAQ:MRNA) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Jul 18
Moderna, Inc.'s (NASDAQ:MRNA) Price Is Right But Growth Is Lacking After Shares Rocket 26%

MODERNA (MRNA): WALLSTREET THREW IT OUT - I’LL PICK IT UP AND CASH THE CHECK

Despite the defunding of US governmental research and health services, Moderna remains in a commanding fundamental position. The company that made its name during the COVID-19 pandemic developing and

More Downside For Moderna Before The Breakthrough

Apr 22

Moderna, Inc.'s (NASDAQ:MRNA) 27% Dip In Price Shows Sentiment Is Matching Revenues

Apr 04
Moderna, Inc.'s (NASDAQ:MRNA) 27% Dip In Price Shows Sentiment Is Matching Revenues

FDA Shake-Up Rocks Moderna Stock As Regulatory Risks Mount (Downgrade)

Mar 31

Moderna: Patent Litigation Win Masks Underperformance, Unlikely To Pay Out

Mar 06

Moderna, Inc.: Working Hard But Competition Is Working Harder

Feb 14
User avatar

Vaccine Expansion Plans Could Shape Future Despite Market Challenges And Legal Risks

Strategic product innovation in combining vaccines could enhance long-term revenue streams and international market positioning.

Moderna, Inc.'s (NASDAQ:MRNA) Business And Shares Still Trailing The Industry

Feb 03
Moderna, Inc.'s (NASDAQ:MRNA) Business And Shares Still Trailing The Industry

Moderna: The Good News Isn't Enough

Feb 03

Moderna: Can They Benefit From Bird Flu? (Rating Upgrade)

Jan 10

Moderna: 2025 Contrarian Play

Dec 31

Moderna: Cutting Costs Might Not Be Enough

Dec 18

Moderna's Fresh Blow As RFK Heads To HHS - A Tough 2025 May Be In Store

Nov 22

Moderna: Assessing The Impact Of GSK's Patent Lawsuit

Oct 22

Moderna: Still Bullish View

Sep 20

Moderna: Fresh Sell-Off On Cost Cutting Initiatives, Short-Term Outlook Troubling

Sep 12

Moderna's Vaccine Progress Undermined By RSV Market Contraction (Rating Downgrade)

Aug 26

Moderna: State Of Play Ahead Of Q2 Earnings, I'm (Temporarily) Pessimistic

Jul 30

Moderna: Really Strong Competition

Jun 30

Moment Of Truth Approaches For Moderna's RSV Vaccine

Jun 18

Moderna: Betting On Bird Flu Rally Is A Poor Strategy For A Value Investor

May 23

Moderna Q1: A Promising Pipeline Is Undervalued

May 15

CEO Compensation Analysis

How has Stéphane Bancel's remuneration changed compared to Moderna's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$3b

Jun 30 2025n/an/a

-US$3b

Mar 31 2025n/an/a

-US$3b

Dec 31 2024US$20mUS$2m

-US$4b

Sep 30 2024n/an/a

-US$2b

Jun 30 2024n/an/a

-US$6b

Mar 31 2024n/an/a

-US$6b

Dec 31 2023US$17mUS$2m

-US$5b

Sep 30 2023n/an/a

-US$3b

Jun 30 2023n/an/a

US$1b

Mar 31 2023n/an/a

US$5b

Dec 31 2022US$19mUS$1m

US$8b

Sep 30 2022n/an/a

US$12b

Jun 30 2022n/an/a

US$14b

Mar 31 2022n/an/a

US$15b

Dec 31 2021US$18mUS$990k

US$12b

Sep 30 2021n/an/a

US$7b

Jun 30 2021n/an/a

US$3b

Mar 31 2021n/an/a

US$598m

Dec 31 2020US$13mUS$946k

-US$747m

Sep 30 2020n/an/a

-US$597m

Jun 30 2020n/an/a

-US$488m

Mar 31 2020n/an/a

-US$505m

Dec 31 2019US$9mUS$921k

-US$514m

Sep 30 2019n/an/a

-US$535m

Jun 30 2019n/an/a

-US$499m

Mar 31 2019n/an/a

-US$459m

Dec 31 2018US$59mUS$863k

-US$402m

Compensation vs Market: Stéphane's total compensation ($USD19.88M) is above average for companies of similar size in the US market ($USD13.36M).

Compensation vs Earnings: Stéphane's compensation has increased whilst the company is unprofitable.

CEO

Stéphane Bancel (52 yo)

14.2yrs
Tenure
US$19,876,180
Compensation

Mr. Stéphane Bancel served as a Board Director at Indigo Agriculture Inc since 2020 until July 2025. Mr Bancel served as an Interim President at Valera LLC. He serves as a CEO and Director at Valera LLC.M...

Leadership Team

NamePositionTenureCompensationOwnership
Stéphane Bancel
CEO & Director14.2yrsUS$19.88m5.62%
$ 685.1m
Stephen Hoge
Presidentno dataUS$9.18m0.41%
$ 50.3m
James Mock
Chief Financial Officer3.3yrsUS$17.21m0.011%
$ 1.3m
Shannon Klinger
Chief Legal Officer & Corporate Secretary4.5yrsUS$17.37m0.014%
$ 1.7m
Jerh Collins
Chief Technical Operations & Quality Officer2.9yrsno datano data
Lavina Talukdar
Senior VP & Head of Investor Relations6.7yrsno datano data
Tracey Franklin
Chief People & Digital Technology Officer6.2yrsno datano data
Melanie Ivarsson
Chief Development Officer5.9yrsno datano data
Dave Johnson
Chief Data & AI Officerno datano datano data
Charbel Haber
Senior VP & Head of Global Regulatory Science5.7yrsno datano data
Jacqueline Miller
Chief Medical Officer5.6yrsno datano data
Patrick Bergstedt
Senior Vice President of Commercial Vaccines5.5yrsno datano data
5.6yrs
Average Tenure
51.5yo
Average Age

Experienced Management: MRNA's management team is seasoned and experienced (5.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Stéphane Bancel
CEO & Director14.8yrsUS$19.88m5.62%
$ 685.1m
Darin Edwards
Executive Directorno datano datano data
Noubar Afeyan
Co-Founder15.9yrsUS$644.37k0.57%
$ 69.4m
Elizabeth Tallett
Independent Director5.4yrsUS$578.40k0.00018%
$ 21.9k
Robert S. Langer
Member of Scientific Advisory Boardno dataUS$538.40kno data
Scott Canute
Member of Technology Advisory Board11.6yrsno datano data
Elizabeth Nabel
Independent Director4.8yrsUS$578.38k0.00079%
$ 96.3k
Fred Regnier
Member of Technology Advisory Board11.6yrsno datano data
Francois Nader
Independent Non Executive Director6yrsUS$578.40k0.0053%
$ 642.5k
Ulrich von Andrian-Werburg
Member of Scientific Advisory Boardno datano datano data
Jack Szostak
Chairman of Scientific Advisory Board11.6yrsno datano data
John Aunins
Member of Technology Advisory Board11.6yrsno datano data
11.6yrs
Average Tenure
66yo
Average Age

Experienced Board: MRNA's board of directors are seasoned and experienced ( 11.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/28 01:42
End of Day Share Price 2025/12/26 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Moderna, Inc. is covered by 45 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullArgus Research Company
Huidong WangBarclays
Harry GillisBerenberg